Latest Whitepapers

Adeno-associated viral vector (AAV) has become a preferred gene therapy delivery modality; however, AAV manufacturing is not without its challenges, whether that is using crude samples, a lack of standardized methods or incompatible techniques.

Despite the success of AAV for gene therapies and vaccines, many challenges still exist within AAV manufacturing. To ensure the safety and efficacy of a therapeutic, it is crucial to accurately determine the percentage of capsids that carry the gene of interest.

A scalable and robust solution for all stages of the gene therapy workflow to meet regulatory standards is essential, however, as the field is more recent, liquid media is the common format even though it can be more expensive and have a shorter shelf life.

Whether scaling up production in-house or using a contractor there are many factors to consider. This whitepaper outlines how outsourcing process development to an experienced provider can improve workflow efficiency and reduce overall costs.

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

mRNA-based therapies, from infectious disease vaccines to genetic disorder treatments, are gaining traction. However, mRNA purification methods must evolve beyond traditional precipitation techniques to meet the demands of large-scale therapeutic production.

For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development. Our BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.

This whitepaper explores how scientists can identify and take advantage of untapped business value in existing lab data.

This whitepaper highlights common challenges in gene therapy development and explores the latest analytical approaches available to combat workflow disruption.

High-fidelity affinity chromatography ligands can support more efficient, cost-effective manufacturing, providing superior yield in a single purification step and accelerating drugs to market.